Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$5.11 +5.1%	$8.40	$3.80 ▼ $47.80	$8.10M	-1.27	62,381 shs	99,836 shs
BCLI Brainstorm Cell Therapeutics	$0.63 +3.6%	$0.97	$0.52 ▼ $6.00	$6.90M	0.12	630,298 shs	27,123 shs
HCWB HCW Biologics	$4.09 -5.8%	$4.52	$3.55 ▼ $100.80	$5.89M	0.66	111,372 shs	29,095 shs
TNFA TNF Pharmaceuticals	$0.10 -1.3%	$0.12	$0.08 ▼ $2.16	$1.43M	1.82	85.46 million shs	23.03 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	0.00%	+14.32%	-43.10%	-33.98%	-86.55%
BCLI Brainstorm Cell Therapeutics	0.00%	+7.86%	-46.54%	-52.61%	-86.33%
HCWB HCW Biologics	0.00%	-11.47%	-13.16%	-54.30%	-82.37%
TNFA TNF Pharmaceuticals	0.00%	+4.34%	+6.65%	-46.53%	+10,099,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	3.0302 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0
BCLI Brainstorm Cell Therapeutics	2.5081 of 5 stars	0.0	5.0	0.0	4.7	2.5	0.8	0.6
HCWB HCW Biologics	2.1652 of 5 stars	3.5	3.0	0.0	0.0	1.6	1.7	0.0
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$31.00	506.65% Upside
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
HCWB HCW Biologics	3.00	Buy	$35.00	755.75% Upside
TNFA TNF Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TNFA, BCLI, ACXP, and HCWB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$31.00
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$2.25 per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
HCWB HCW Biologics	$1.45M	4.07	N/A	N/A	($6.08) per share	-0.67
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	$2.87 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$10.69	N/A	N/A	N/A	N/A	-436.83%	-192.25%	N/A
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.36	N/A	N/A	N/A	N/A	N/A	-519.50%	N/A
HCWB HCW Biologics	-$30.02M	-$23.25	N/A	∞	N/A	-1,712.94%	N/A	-90.09%	N/A
TNFA TNF Pharmaceuticals	-$23.36M	-$6.67	N/A	∞	N/A	N/A	-97.38%	-37.37%	8/18/2025 (Estimated)

Latest TNFA, BCLI, ACXP, and HCWB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	ACXP Acurx Pharmaceuticals	-$2.00	-$1.89	+$0.11	-$1.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
TNFA TNF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	2.38	1.93
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
HCWB HCW Biologics	N/A	0.07	0.07
TNFA TNF Pharmaceuticals	N/A	1.37	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
BCLI Brainstorm Cell Therapeutics	14.33%
HCWB HCW Biologics	2.96%
TNFA TNF Pharmaceuticals	9.64%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	20.30%
BCLI Brainstorm Cell Therapeutics	11.15%
HCWB HCW Biologics	42.70%
TNFA TNF Pharmaceuticals	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	1.59 million	1.26 million	Optionable
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
HCWB HCW Biologics	40	1.44 million	825,000	Not Optionable
TNFA TNF Pharmaceuticals	6	14.18 million	14.12 million	N/A

TNFA, BCLI, ACXP, and HCWB Headlines

Recent News About These Companies

TNF Pharmaceuticals Inc Ordinary Shares TNFA - Morningstar

July 11, 2025 | morningstar.comM

TNF Pharmaceuticals, Inc. (TNFA) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

June 25, 2025 | finance.yahoo.com

TNF Pharmaceuticals Amends Bylaws to Alter Voting Rules

May 9, 2025 | tipranks.com

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

May 8, 2025 | businesswire.com

TNF Pharmaceuticals uses AI to refine patient selection for trials

April 24, 2025 | uk.investing.com

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

April 22, 2025 | finance.yahoo.com

TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays Bearish

April 22, 2025 | msn.com

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

April 17, 2025 | finance.yahoo.com

TNF Pharmaceuticals, Inc. Common Stock (TNFA) Short Interest

April 3, 2025 | nasdaq.com

TNF Pharmaceuticals faces Nasdaq delisting over price

March 23, 2025 | investing.com

TNF Pharmaceuticals, Inc. Common Stock

March 20, 2025 | fxempire.comF

TNF Pharmaceuticals shares R&D progress on Isomyosamine

March 12, 2025 | uk.investing.com

TNF Pharmaceuticals initiates isomyosamine trial

February 25, 2025 | markets.businessinsider.com

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

February 25, 2025 | businesswire.com

TNFA stock touches 52-week low at $0.48 amid market challenges

February 14, 2025 | msn.com

TNFA stock touches 52-week low at $1.02 amid market challenges

January 30, 2025 | msn.com

How Does TNF Pharmaceuticals Inc (TNFA) Stack Up Against Its Industry Peers?

January 30, 2025 | bovnews.comB

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

January 29, 2025 | tmcnet.com

TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s

January 29, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNFA, BCLI, ACXP, and HCWB Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$5.11 +0.25 (+5.14%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.04 -0.08 (-1.47%)

As of 08/15/2025 07:59 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.63 +0.02 (+3.65%)

As of 08/15/2025 03:58 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

HCW Biologics NASDAQ:HCWB

$4.09 -0.25 (-5.76%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$4.37 +0.28 (+6.85%)

As of 08/15/2025 07:39 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

TNF Pharmaceuticals NASDAQ:TNFA

$0.10 0.00 (-1.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.10 0.00 (-1.88%)

As of 08/15/2025 07:59 PM Eastern

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time